SCHEMBL21363719

SCHEMBL21363719

Cc1ccc2ccc(Cc3cc4ccccc4cn3)cc2c1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2A6 P11509 5/20 0.50
TDP1 Q9NUW8 1/20 0.50
PDE10A Q9Y233 5/20 0.45
BACE1 P56817 1/20 0.43
CYP1A2 P05177 4/20 0.42
HTR2A P28223 1/20 0.41
HTR2C P28335 1/20 0.41
HTR2B P41595 1/20 0.41
MAPK8 P45983 1/20 0.40
GSK3A P49840 1/20 0.40
MAPK10 P53779 1/20 0.40
HIPK1 Q86Z02 1/20 0.40
RIOK2 Q9BVS4 1/20 0.40
SNRK Q9NRH2 1/20 0.40
ATM Q13315 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
ADORA2A P29274 1/20 0.39
ADORA1 P30542 1/20 0.39
CYP2D6 P10635 1/20 0.38
NFKB1 P19838 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23396667 0.88 CYP1A2 (0.47) CYP2A6TDP1PDE10ACYP1A2
SCHEMBL23715914 0.86 CYP1A2 (0.48) CYP2A6TDP1PDE10ACYP1A2HTR2B
SCHEMBL21363718 0.85 CYP19A1 (0.41) CYP2A6PDE10ACYP1A2
SCHEMBL3119876 0.83 CYP1A2 (0.46) CYP2A6PDE10ACYP1A2HTR2CHTR2B
SCHEMBL22685142 0.83 PDE10A (0.42) CYP2A6PDE10ACYP1A2
SCHEMBL22683771 0.78 PDE10A (0.48) CYP2A6PDE10ABACE1CYP1A2HTR2A
SCHEMBL21515675 0.77 NQO2 (0.44) CYP2A6TDP1PDE10ABACE1CYP1A2
SCHEMBL21031190 0.76 PDE10A (0.52) CYP2A6PDE10ABACE1CYP1A2ATM
SCHEMBL3121339 0.76 HTR2B (0.50) CYP2A6TDP1PDE10ACYP1A2HTR2B
SCHEMBL21951174 0.74 CYP1A2 (0.44) CYP2A6PDE10ABACE1CYP1A2HTR2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10815226-B2 Heteroaryl compounds as inhibitors of necrosis, composition and application thereof ACCRO BIOSCIENCE INC. (KY) 2020-10-27 US disclosed
US-20200048223-A1 WNT SIGNALING PATHWAY INHIBITORS AND THERAPEUTIC APPLICATIONS THEREOF Suzhou Yunxuan Yiyao Keji Youxian Gongsi (CN) 2020-02-13 US disclosed
US-10450300-B2 Wnt signaling pathway inhibitors and therapeutic applications thereof Suzhou Yunxuan Yiyao Keji Youxian Gongsi (CN) 2019-10-22 US disclosed
US-20190284180-A1 HETEROARYL COMPOUNDS AS INHIBITORS OF NECROSIS, COMPOSITION AND APPLICATION THEREOF ACCRO BIOSCIENCE (HK) LIMITED (HK) 2019-09-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10450300-B2 Wnt signaling pathway inhibitors and therapeutic applications thereof WNT1, WNT3A, CTNNB1 CYP2A6 2710/4885TDP1 4679/4885PDE10A 2312/4885
US-20200048223-A1 WNT SIGNALING PATHWAY INHIBITORS AND THERAPEUTIC APPLICATIONS THEREOF WNT1, WNT3A, CTNNB1 CYP2A6 2710/4885TDP1 4679/4885PDE10A 2312/4885
US-10815226-B2 Heteroaryl compounds as inhibitors of necrosis, composition and application thereof LITAF, BAX, TNF CYP2A6 1173/4885TDP1 1419/4885PDE10A 3389/4885
US-20190284180-A1 HETEROARYL COMPOUNDS AS INHIBITORS OF NECROSIS, COMPOSITION AND APPLICATION THEREOF LITAF, BAX, TNF CYP2A6 1173/4885TDP1 1419/4885PDE10A 3389/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.